Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 10:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ustekinumab 90 mg Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease

NCT03782376
View directory record Official record
Conditions
Crohn Disease
Interventions
Ustekinumab approximately 6 mg/kg (IV), Placebo (SC), Placebo (IV), Ustekinumab 90 mg (SC) Group 1, Ustekinumab 90 mg (SC) Group 2
Drug
Lead sponsor
Janssen-Cilag Ltd.
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
28
States / cities
La Jolla, California • Colorado Springs, Colorado • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT05335356
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
Stelara, Bmab1200
Biological
Lead sponsor
Biocon Biologics UK Ltd
Industry
Eligibility
18 Years to 80 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Mayfield Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 1Phase 2 Interventional

Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology

NCT03366142
View directory record Official record
Conditions
LAD1
Interventions
Ustekinumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

NCT01389973
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
ustekinumab 90 mg, ustekinumab 45 mg, ustekinumab 180 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Jacksonville, Florida • Miami, Florida • Naples, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2016 · Synced Sep 24, 2026, 10:22 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis

NCT02438787
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
19
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT02407236
View directory record Official record
Conditions
Colitis, Ulcerative, Inflammatory Bowel Diseases
Interventions
Placebo IV, Placebo SC, Ustekinumab IV, Ustekinumab SC
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
68
States / cities
Birmingham, Alabama • La Mirada, California • Los Angeles, California + 65 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 24, 2026, 10:22 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease

NCT04978493
View directory record Official record
Conditions
Crohn Disease
Interventions
BI 706321, Ustekinumab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
Northridge, California • Hialeah, Florida • Inverness, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis

NCT01009086
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
26
States / cities
Encinitas, California • La Jolla, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age

NCT02698475
View directory record Official record
Conditions
Psoriasis
Interventions
Ustekinumab 0.75 mg/kg, Ustekinumab 45 mg, Ustekinumab 90 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
6 Years to 11 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus

NCT02349061
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Ustekinumab IV, Placebo Infusion, Placebo SC, Ustekinumab SC, Concomitant Medication
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
12
States / cities
Huntsville, Alabama • Beverly Hills, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Sep 24, 2026, 10:22 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

NCT03517722
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Placebo, Ustekinumab (approximately 6 mg/kg), Ustekinumab 90 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
16 Years to 75 Years
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Vestavia Hills, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

NCT01645280
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo + methotrexate (MTX) (Group 1), Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4), CNTO 1959 + MTX (Group 5)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Palm Harbor, Florida • Rock Island, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease

NCT00265122
View directory record Official record
Conditions
Crohn Disease
Interventions
Ustekinumab 90 mg, Ustekinumab 4.5 mg/kg, Placebo SC, Placebo IV
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
50
States / cities
Scottsdale, Arizona • Anaheim, California • Sacramento, California + 47 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

NCT02968108
View directory record Official record
Conditions
Crohn Disease
Interventions
Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
9
States / cities
Los Angeles, California • Hartford, Connecticut • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents

NCT01077362
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
placebo, ustekinumab 45 mg, ustekinumab 90 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 1 Interventional Results available

Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome

NCT04093531
View directory record Official record
Conditions
Primary Sjögren Syndrome
Interventions
Ustekinumab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Not applicable Interventional Results available

Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis

NCT01090063
View directory record Official record
Conditions
Moderate to Severe Palmar Plantar Psoriasis
Interventions
Ustekinumab
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 24, 2026, 10:22 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

NCT03358706
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg, Warfarin 10 mg, Vitamin K 10 mg, Omeprazole 20 mg, Dextromethorphan 30 mg, Caffeine 100 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
3
States / cities
Cypress, California • Miami Springs, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease

NCT01713400
View directory record Official record
Conditions
Graft vs. Host Disease
Interventions
Ustekinumab, Placebo, Tacrolimus (TAC), Sirolimus
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

NCT01550744
View directory record Official record
Conditions
Psoriasis
Interventions
Ustekinumab 45 mg, Ustekinumab 90 mg, Placebo
Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Bakersfield, California • Irvine, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 24, 2026, 10:22 PM EDT
Terminated Phase 3 Interventional Results available

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

NCT01708603
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
67
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2020 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab

NCT02203032
View directory record Official record
Conditions
Psoriasis
Interventions
Ustekinumab, Guselkumab, Placebo for ustekinumab, Placebo for guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
29
States / cities
Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Sep 24, 2026, 10:22 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

NCT01708629
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
74
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Sep 24, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

NCT00307437
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
Drug
Lead sponsor
Centocor Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 24, 2026, 10:22 PM EDT